nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PSMA1—mouth—pharynx cancer	0.0274	0.0558	CbGeAlD
Bortezomib—PSMD1—parotid gland—pharynx cancer	0.016	0.0326	CbGeAlD
Bortezomib—PSMA1—epithelium—pharynx cancer	0.0159	0.0325	CbGeAlD
Bortezomib—PSMD1—saliva-secreting gland—pharynx cancer	0.0153	0.0313	CbGeAlD
Bortezomib—CTSG—trachea—pharynx cancer	0.0147	0.0299	CbGeAlD
Bortezomib—PSMD2—parotid gland—pharynx cancer	0.0142	0.0289	CbGeAlD
Bortezomib—PSMB8—parotid gland—pharynx cancer	0.0141	0.0287	CbGeAlD
Bortezomib—PSMD2—saliva-secreting gland—pharynx cancer	0.0136	0.0277	CbGeAlD
Bortezomib—PSMB8—saliva-secreting gland—pharynx cancer	0.0135	0.0275	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—pharynx cancer	0.0128	0.0261	CbGeAlD
Bortezomib—PSMB5—parotid gland—pharynx cancer	0.0125	0.0254	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—pharynx cancer	0.0123	0.025	CbGeAlD
Bortezomib—PSMB5—saliva-secreting gland—pharynx cancer	0.0119	0.0243	CbGeAlD
Bortezomib—PSMD1—trachea—pharynx cancer	0.0118	0.0241	CbGeAlD
Bortezomib—PSMB1—parotid gland—pharynx cancer	0.0109	0.0222	CbGeAlD
Bortezomib—PSMB2—parotid gland—pharynx cancer	0.0106	0.0216	CbGeAlD
Bortezomib—PSMD2—trachea—pharynx cancer	0.0105	0.0214	CbGeAlD
Bortezomib—PSMB1—saliva-secreting gland—pharynx cancer	0.0104	0.0213	CbGeAlD
Bortezomib—PSMB8—trachea—pharynx cancer	0.0104	0.0212	CbGeAlD
Bortezomib—PSMB2—saliva-secreting gland—pharynx cancer	0.0102	0.0207	CbGeAlD
Bortezomib—PSMA1—head—pharynx cancer	0.0099	0.0202	CbGeAlD
Bortezomib—PSMD1—spinal cord—pharynx cancer	0.00935	0.019	CbGeAlD
Bortezomib—PSMB5—trachea—pharynx cancer	0.00921	0.0188	CbGeAlD
Bortezomib—SLC31A1—parotid gland—pharynx cancer	0.0092	0.0187	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—pharynx cancer	0.00913	0.0186	CbGeAlD
Bortezomib—SLC31A1—saliva-secreting gland—pharynx cancer	0.00882	0.018	CbGeAlD
Bortezomib—PSMD2—spinal cord—pharynx cancer	0.00828	0.0169	CbGeAlD
Bortezomib—PSMB1—trachea—pharynx cancer	0.00805	0.0164	CbGeAlD
Bortezomib—PSMB2—trachea—pharynx cancer	0.00785	0.016	CbGeAlD
Bortezomib—PSMD2—head—pharynx cancer	0.00736	0.015	CbGeAlD
Bortezomib—PSMB5—spinal cord—pharynx cancer	0.00727	0.0148	CbGeAlD
Bortezomib—CTSG—lymph node—pharynx cancer	0.00722	0.0147	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—pharynx cancer	0.00701	0.0143	CbGeAlD
Bortezomib—PSMA1—lymph node—pharynx cancer	0.00693	0.0141	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—pharynx cancer	0.00684	0.0139	CbGeAlD
Bortezomib—SLC31A1—trachea—pharynx cancer	0.0068	0.0139	CbGeAlD
Bortezomib—PSMB1—spinal cord—pharynx cancer	0.00635	0.0129	CbGeAlD
Bortezomib—PSMB2—spinal cord—pharynx cancer	0.0062	0.0126	CbGeAlD
Bortezomib—PSMD1—lymph node—pharynx cancer	0.00582	0.0119	CbGeAlD
Bortezomib—PSMB1—head—pharynx cancer	0.00565	0.0115	CbGeAlD
Bortezomib—PSMB2—head—pharynx cancer	0.00551	0.0112	CbGeAlD
Bortezomib—SLC31A1—spinal cord—pharynx cancer	0.00537	0.0109	CbGeAlD
Bortezomib—PSMD2—lymph node—pharynx cancer	0.00515	0.0105	CbGeAlD
Bortezomib—PSMB8—lymph node—pharynx cancer	0.00512	0.0104	CbGeAlD
Bortezomib—SLC31A1—head—pharynx cancer	0.00477	0.00972	CbGeAlD
Bortezomib—PSMB5—lymph node—pharynx cancer	0.00452	0.00922	CbGeAlD
Bortezomib—CYP1A1—mouth—pharynx cancer	0.00449	0.00914	CbGeAlD
Bortezomib—PSMB1—lymph node—pharynx cancer	0.00395	0.00806	CbGeAlD
Bortezomib—PSMB2—lymph node—pharynx cancer	0.00386	0.00786	CbGeAlD
Bortezomib—SLC31A1—lymph node—pharynx cancer	0.00334	0.00681	CbGeAlD
Bortezomib—CYP1A1—parotid gland—pharynx cancer	0.00313	0.00637	CbGeAlD
Bortezomib—CYP1A1—epithelium—pharynx cancer	0.00261	0.00532	CbGeAlD
Bortezomib—CYP1A1—trachea—pharynx cancer	0.00231	0.0047	CbGeAlD
Bortezomib—PTGS1—epithelium—pharynx cancer	0.00229	0.00467	CbGeAlD
Bortezomib—CYP2D6—brainstem—pharynx cancer	0.00212	0.00431	CbGeAlD
Bortezomib—PTGS1—trachea—pharynx cancer	0.00203	0.00413	CbGeAlD
Bortezomib—PSMD2—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00189	0.00371	CbGpPWpGaD
Bortezomib—CYP2C8—Biological oxidations—CNDP2—pharynx cancer	0.00182	0.00358	CbGpPWpGaD
Bortezomib—CYP1A1—Biological oxidations—ADH7—pharynx cancer	0.0018	0.00353	CbGpPWpGaD
Bortezomib—PSMA1—Apoptosis—CDH1—pharynx cancer	0.00179	0.00352	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—CDH1—pharynx cancer	0.00178	0.0035	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—CDH1—pharynx cancer	0.00178	0.00349	CbGpPWpGaD
Bortezomib—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.00167	0.00327	CbGpPWpGaD
Bortezomib—CYP2C8—Biological oxidations—ADH7—pharynx cancer	0.00165	0.00324	CbGpPWpGaD
Bortezomib—PSMB5—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00165	0.00324	CbGpPWpGaD
Bortezomib—PSMB1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00165	0.00324	CbGpPWpGaD
Bortezomib—PSMB2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00165	0.00324	CbGpPWpGaD
Bortezomib—CYP2C19—Biological oxidations—CNDP2—pharynx cancer	0.00163	0.0032	CbGpPWpGaD
Bortezomib—PSMB8—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00163	0.00319	CbGpPWpGaD
Bortezomib—PSMB1—Stabilization of p53—TP53—pharynx cancer	0.00162	0.00319	CbGpPWpGaD
Bortezomib—PSMB2—Stabilization of p53—TP53—pharynx cancer	0.00162	0.00319	CbGpPWpGaD
Bortezomib—PSMB5—Stabilization of p53—TP53—pharynx cancer	0.00162	0.00319	CbGpPWpGaD
Bortezomib—CYP1A1—head—pharynx cancer	0.00162	0.0033	CbGeAlD
Bortezomib—PSMA1—S Phase—CCND1—pharynx cancer	0.00161	0.00316	CbGpPWpGaD
Bortezomib—PTGS1—spinal cord—pharynx cancer	0.0016	0.00326	CbGeAlD
Bortezomib—PSMB8—Stabilization of p53—TP53—pharynx cancer	0.0016	0.00314	CbGpPWpGaD
Bortezomib—PSMD1—S Phase—CCND1—pharynx cancer	0.0016	0.00314	CbGpPWpGaD
Bortezomib—PSMD2—S Phase—CCND1—pharynx cancer	0.00159	0.00313	CbGpPWpGaD
Bortezomib—CYP1A1—Biological oxidations—ADH1B—pharynx cancer	0.00158	0.0031	CbGpPWpGaD
Bortezomib—PSMB2—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00151	0.00296	CbGpPWpGaD
Bortezomib—PSMB5—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00151	0.00296	CbGpPWpGaD
Bortezomib—PSMB1—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00151	0.00296	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—CNDP2—pharynx cancer	0.0015	0.00294	CbGpPWpGaD
Bortezomib—PSMA1—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00149	0.00293	CbGpPWpGaD
Bortezomib—PSMD1—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00148	0.00292	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—CNDP2—pharynx cancer	0.00148	0.00292	CbGpPWpGaD
Bortezomib—PSMB8—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00148	0.00292	CbGpPWpGaD
Bortezomib—PSMD2—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00148	0.0029	CbGpPWpGaD
Bortezomib—CYP2C19—Biological oxidations—ADH7—pharynx cancer	0.00147	0.00289	CbGpPWpGaD
Bortezomib—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00146	0.00287	CbGpPWpGaD
Bortezomib—CYP2C8—Biological oxidations—ADH1B—pharynx cancer	0.00145	0.00284	CbGpPWpGaD
Bortezomib—PSMB2—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00144	0.00284	CbGpPWpGaD
Bortezomib—PSMB5—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00144	0.00284	CbGpPWpGaD
Bortezomib—PSMB1—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00144	0.00284	CbGpPWpGaD
Bortezomib—PTGS1—head—pharynx cancer	0.00142	0.0029	CbGeAlD
Bortezomib—PSMB8—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00142	0.0028	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—CDH1—pharynx cancer	0.00136	0.00267	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—CDH1—pharynx cancer	0.00136	0.00267	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—CDH1—pharynx cancer	0.00136	0.00267	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—ADH7—pharynx cancer	0.00135	0.00266	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—ADH7—pharynx cancer	0.00134	0.00264	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—CDH1—pharynx cancer	0.00134	0.00263	CbGpPWpGaD
Bortezomib—CYP2C19—Biological oxidations—ADH1B—pharynx cancer	0.00129	0.00254	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—CNDP2—pharynx cancer	0.00127	0.00249	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—CNDP2—pharynx cancer	0.00122	0.00239	CbGpPWpGaD
Bortezomib—PSMB5—S Phase—CCND1—pharynx cancer	0.00122	0.00239	CbGpPWpGaD
Bortezomib—PSMB1—S Phase—CCND1—pharynx cancer	0.00122	0.00239	CbGpPWpGaD
Bortezomib—PSMB2—S Phase—CCND1—pharynx cancer	0.00122	0.00239	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—CNDP2—pharynx cancer	0.00121	0.00238	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—CNDP2—pharynx cancer	0.00121	0.00237	CbGpPWpGaD
Bortezomib—PSMB8—S Phase—CCND1—pharynx cancer	0.0012	0.00236	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—ADH1B—pharynx cancer	0.00119	0.00233	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—ADH1B—pharynx cancer	0.00118	0.00231	CbGpPWpGaD
Bortezomib—CYP2D6—head—pharynx cancer	0.00117	0.00238	CbGeAlD
Bortezomib—CYP1A2—Biological oxidations—ADH7—pharynx cancer	0.00115	0.00225	CbGpPWpGaD
Bortezomib—CYP1A1—lymph node—pharynx cancer	0.00113	0.00231	CbGeAlD
Bortezomib—PSMB1—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00113	0.00222	CbGpPWpGaD
Bortezomib—PSMB5—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00113	0.00222	CbGpPWpGaD
Bortezomib—PSMB2—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00113	0.00222	CbGpPWpGaD
Bortezomib—PSMB8—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00111	0.00219	CbGpPWpGaD
Bortezomib—PSMA1—Disease—B4GALT5—pharynx cancer	0.0011	0.00217	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ADH7—pharynx cancer	0.0011	0.00217	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle Checkpoints—TP53—pharynx cancer	0.0011	0.00216	CbGpPWpGaD
Bortezomib—PSMD1—Disease—B4GALT5—pharynx cancer	0.0011	0.00216	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ADH7—pharynx cancer	0.0011	0.00216	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle Checkpoints—TP53—pharynx cancer	0.0011	0.00215	CbGpPWpGaD
Bortezomib—PSMD2—Disease—B4GALT5—pharynx cancer	0.00109	0.00215	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ADH7—pharynx cancer	0.00109	0.00215	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00109	0.00214	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD79A—pharynx cancer	0.00108	0.00212	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD79A—pharynx cancer	0.00107	0.00211	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD79A—pharynx cancer	0.00107	0.0021	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—ADH1B—pharynx cancer	0.00101	0.00198	CbGpPWpGaD
Bortezomib—PTGS1—lymph node—pharynx cancer	0.000997	0.00203	CbGeAlD
Bortezomib—PSMA1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000987	0.00194	CbGpPWpGaD
Bortezomib—PSMD1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000983	0.00193	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—CNDP2—pharynx cancer	0.000979	0.00192	CbGpPWpGaD
Bortezomib—PSMD2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000978	0.00192	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ADH1B—pharynx cancer	0.000967	0.0019	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ADH1B—pharynx cancer	0.000962	0.00189	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ADH1B—pharynx cancer	0.000958	0.00188	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—B4GALT5—pharynx cancer	0.000924	0.00181	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CNDP2—pharynx cancer	0.000924	0.00181	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CNDP2—pharynx cancer	0.000924	0.00181	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CNDP2—pharynx cancer	0.000924	0.00181	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—B4GALT5—pharynx cancer	0.000919	0.00181	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—B4GALT5—pharynx cancer	0.000915	0.0018	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CNDP2—pharynx cancer	0.000911	0.00179	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—ADH7—pharynx cancer	0.000886	0.00174	CbGpPWpGaD
Bortezomib—PSMA1—Apoptosis—TP53—pharynx cancer	0.00088	0.00173	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TP53—pharynx cancer	0.000876	0.00172	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—EGFR—pharynx cancer	0.000872	0.00171	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TP53—pharynx cancer	0.000872	0.00171	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—EGFR—pharynx cancer	0.000868	0.00171	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—EGFR—pharynx cancer	0.000864	0.0017	CbGpPWpGaD
Bortezomib—PSMB1—Disease—B4GALT5—pharynx cancer	0.000836	0.00164	CbGpPWpGaD
Bortezomib—PSMB2—Disease—B4GALT5—pharynx cancer	0.000836	0.00164	CbGpPWpGaD
Bortezomib—PSMB5—Disease—B4GALT5—pharynx cancer	0.000836	0.00164	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ADH7—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ADH7—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ADH7—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle Checkpoints—TP53—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle Checkpoints—TP53—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle Checkpoints—TP53—pharynx cancer	0.000835	0.00164	CbGpPWpGaD
Bortezomib—PSMB8—Disease—B4GALT5—pharynx cancer	0.000824	0.00162	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ADH7—pharynx cancer	0.000824	0.00162	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle Checkpoints—TP53—pharynx cancer	0.000823	0.00162	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD79A—pharynx cancer	0.000818	0.00161	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD79A—pharynx cancer	0.000818	0.00161	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD79A—pharynx cancer	0.000818	0.00161	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD79A—pharynx cancer	0.000806	0.00158	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—ADH1B—pharynx cancer	0.000776	0.00153	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—pharynx cancer	0.000773	0.00152	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—pharynx cancer	0.000773	0.00152	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000748	0.00147	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000748	0.00147	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000748	0.00147	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000738	0.00145	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ADH1B—pharynx cancer	0.000733	0.00144	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ADH1B—pharynx cancer	0.000733	0.00144	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ADH1B—pharynx cancer	0.000733	0.00144	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ADH1B—pharynx cancer	0.000722	0.00142	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—B4GALT5—pharynx cancer	0.0007	0.00138	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—B4GALT5—pharynx cancer	0.0007	0.00138	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—B4GALT5—pharynx cancer	0.0007	0.00138	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—B4GALT5—pharynx cancer	0.00069	0.00136	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TP53—pharynx cancer	0.000667	0.00131	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TP53—pharynx cancer	0.000667	0.00131	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TP53—pharynx cancer	0.000667	0.00131	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—EGFR—pharynx cancer	0.000661	0.0013	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—EGFR—pharynx cancer	0.000661	0.0013	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—EGFR—pharynx cancer	0.000661	0.0013	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TP53—pharynx cancer	0.000657	0.00129	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD79A—pharynx cancer	0.000655	0.00129	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—EGFR—pharynx cancer	0.000652	0.00128	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD79A—pharynx cancer	0.000652	0.00128	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD79A—pharynx cancer	0.000648	0.00127	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CDH1—pharynx cancer	0.000601	0.00118	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CDH1—pharynx cancer	0.000598	0.00118	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CDH1—pharynx cancer	0.000596	0.00117	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000547	0.00107	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000545	0.00107	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000542	0.00106	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD79A—pharynx cancer	0.000496	0.000975	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD79A—pharynx cancer	0.000496	0.000975	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD79A—pharynx cancer	0.000496	0.000975	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pharynx cancer	0.000493	0.000968	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pharynx cancer	0.000493	0.000968	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—CCND1—pharynx cancer	0.000489	0.000961	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD79A—pharynx cancer	0.000489	0.000961	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—CCND1—pharynx cancer	0.000487	0.000956	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—CCND1—pharynx cancer	0.000485	0.000952	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CNDP2—pharynx cancer	0.000483	0.000949	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CDH1—pharynx cancer	0.000456	0.000895	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CDH1—pharynx cancer	0.000456	0.000895	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CDH1—pharynx cancer	0.000456	0.000895	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CDH1—pharynx cancer	0.000449	0.000882	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ADH7—pharynx cancer	0.000437	0.000858	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000415	0.000815	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000415	0.000815	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000415	0.000815	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000409	0.000803	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ADH1B—pharynx cancer	0.000383	0.000752	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—CCND1—pharynx cancer	0.000371	0.000728	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—CCND1—pharynx cancer	0.000371	0.000728	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—CCND1—pharynx cancer	0.000371	0.000728	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—B4GALT5—pharynx cancer	0.000366	0.000719	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—CCND1—pharynx cancer	0.000366	0.000718	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CDH1—pharynx cancer	0.000365	0.000716	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CDH1—pharynx cancer	0.000363	0.000713	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CDH1—pharynx cancer	0.000361	0.00071	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—EGFR—pharynx cancer	0.000352	0.000691	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—EGFR—pharynx cancer	0.00035	0.000687	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—EGFR—pharynx cancer	0.000348	0.000684	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CNDP2—pharynx cancer	0.00034	0.000668	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—pharynx cancer	0.000322	0.000633	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—pharynx cancer	0.000321	0.00063	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—pharynx cancer	0.000319	0.000627	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CNDP2—pharynx cancer	0.000312	0.000613	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADH7—pharynx cancer	0.000308	0.000605	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADH7—pharynx cancer	0.000282	0.000554	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CNDP2—pharynx cancer	0.000278	0.000547	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CDH1—pharynx cancer	0.000276	0.000543	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CDH1—pharynx cancer	0.000276	0.000543	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CDH1—pharynx cancer	0.000276	0.000543	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CDH1—pharynx cancer	0.000272	0.000535	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADH1B—pharynx cancer	0.00027	0.00053	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—EGFR—pharynx cancer	0.000266	0.000523	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—EGFR—pharynx cancer	0.000266	0.000523	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—EGFR—pharynx cancer	0.000266	0.000523	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—EGFR—pharynx cancer	0.000263	0.000516	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—B4GALT5—pharynx cancer	0.000258	0.000507	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CNDP2—pharynx cancer	0.000256	0.000503	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CNDP2—pharynx cancer	0.000254	0.000499	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADH7—pharynx cancer	0.000252	0.000495	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADH1B—pharynx cancer	0.000247	0.000486	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—pharynx cancer	0.000244	0.00048	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—pharynx cancer	0.000244	0.00048	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—pharynx cancer	0.000244	0.00048	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—pharynx cancer	0.000241	0.000473	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—B4GALT5—pharynx cancer	0.000236	0.000464	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADH7—pharynx cancer	0.000232	0.000455	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADH7—pharynx cancer	0.00023	0.000451	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADH1B—pharynx cancer	0.000221	0.000434	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CNDP2—pharynx cancer	0.000217	0.000426	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—pharynx cancer	0.000213	0.000419	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—pharynx cancer	0.000212	0.000417	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—pharynx cancer	0.000211	0.000415	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—B4GALT5—pharynx cancer	0.000211	0.000415	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADH1B—pharynx cancer	0.000203	0.000399	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADH1B—pharynx cancer	0.000201	0.000396	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—pharynx cancer	0.000197	0.000387	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADH7—pharynx cancer	0.000196	0.000385	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—pharynx cancer	0.000196	0.000385	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—pharynx cancer	0.000195	0.000383	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—B4GALT5—pharynx cancer	0.000194	0.000381	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—B4GALT5—pharynx cancer	0.000192	0.000378	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCND1—pharynx cancer	0.000176	0.000345	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCND1—pharynx cancer	0.000175	0.000344	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCND1—pharynx cancer	0.000174	0.000342	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADH1B—pharynx cancer	0.000172	0.000338	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CNDP2—pharynx cancer	0.000167	0.000329	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—B4GALT5—pharynx cancer	0.000164	0.000323	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—pharynx cancer	0.000162	0.000318	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—pharynx cancer	0.000162	0.000318	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—pharynx cancer	0.000162	0.000318	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—pharynx cancer	0.000159	0.000313	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADH7—pharynx cancer	0.000151	0.000297	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—pharynx cancer	0.000149	0.000293	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—pharynx cancer	0.000149	0.000293	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—pharynx cancer	0.000149	0.000293	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—pharynx cancer	0.000147	0.000289	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—pharynx cancer	0.000138	0.000271	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—pharynx cancer	0.000137	0.00027	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—pharynx cancer	0.000137	0.000268	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—pharynx cancer	0.000133	0.000262	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—pharynx cancer	0.000133	0.000262	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—pharynx cancer	0.000133	0.000262	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADH1B—pharynx cancer	0.000133	0.000261	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—pharynx cancer	0.000131	0.000258	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	0.000127	0.000249	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—pharynx cancer	0.000116	0.000227	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—pharynx cancer	0.000115	0.000226	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—pharynx cancer	0.000115	0.000225	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—pharynx cancer	0.000104	0.000205	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—pharynx cancer	0.000104	0.000205	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—pharynx cancer	0.000104	0.000205	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—pharynx cancer	0.000103	0.000202	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—pharynx cancer	8.77e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—pharynx cancer	8.77e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—pharynx cancer	8.77e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—pharynx cancer	8.65e-05	0.00017	CbGpPWpGaD
